Journal of Diabetes Research (Jan 2019)

The Association between Metabolic Syndrome and Morbid Events in Type 2 Diabetes after a 7-Year Community Management: Beijing Community Diabetes Study 17

  • Guang-Ran Yang,
  • Ming-Xia Yuan,
  • Han-Jing Fu,
  • Gang Wan,
  • Dongmei Li,
  • Timothy D. Dye,
  • Liang-Xiang Zhu,
  • Rong-Rong Xie,
  • Yu-Jie Lv,
  • Jian-Dong Zhang,
  • Xue-Ping Du,
  • Yu-Ling Li,
  • Yu Ji,
  • Yue Li,
  • Xue-Li Cui,
  • Zi-Ming Wang,
  • Shu-Yan Cheng,
  • De-Yuan Liu,
  • Qian Wang,
  • Li Zhou,
  • Ying Gao,
  • Shen-Yuan Yuan

DOI
https://doi.org/10.1155/2019/5237371
Journal volume & issue
Vol. 2019

Abstract

Read online

Background. To examine the association between morbid events and metabolic syndrome (MS) in patients with type 2 diabetes mellitus (T2DM). Methods. A prospective, longitudinal, multicenter study was conducted at 13 community health centers associated with Beijing Tongren Hospital. From 2008 to 2015, there have been 3,525 T2DM patients being managed based on the Chinese guideline for T2DM. The morbid events included macrovascular events, diabetic kidney disease, ophthalmologic events, cancer, and all-cause death. Results. At baseline, there were 2,708 people with MS and 817 without MS. After a seven-year management, there were 351 (12.96%) events in MS people and 74 (9.06%) events in people without MS (p=0.003). The prevalence of macrovascular events (6.06%) was much higher in MS people than in people without MS (3.79%, p=0.013). Cox regression analysis showed an association between MS and morbid events even after adjusting for confounding variables (adjusted hazard ratio=1.44). MS was also associated with macrovascular events (adjusted hazard ratio=1.96). The occurrence of morbid events and macrovascular events was increased when the numbers of metabolic abnormalities were 1, 2, 3, and 4 (p<0.001). There was no continuously statistically significant difference in the cumulative prevalence of morbid events between patients with MS and patients without MS during the first five years. However, after six or seven years, the cumulative prevalence of morbid events in patients with MS was continuously significantly higher than that in patients without MS (11.00% vs. 8.20%, 12.96% vs. 9.06%, p<0.05). Conclusions. T2DM with MS had higher incidence of morbid events, especially cardiovascular events, even after integrated management. The occurrence of morbid and macrovascular events increased as the number of metabolic abnormalities increased. MS was associated with increased risk of morbid events by 44% and macrovascular events by 96%. It would take at least six years to observe the association between MS and morbid events in T2DM.